

Fig. S1 Mean baseline alcohol intake between studies

Alcohol intake averaged over the baseline periods in the exenatide study and the liraglutide study. Symbols represent individual monkeys, lines connect data points for the subjects that participated in both studies (n=16), isolated points represents monkeys that were tested only with exenatide/vehicle (n=8) or only with liraglutide/vehicle (n=8). Total group size: n=32.

Table S1

Exenatide plasma levels, pilot study

	Monkey O8635	Monkey O8756	Monkey O8684
Baseline	0.05	0.03	0.08
Week 1	0.13	0.04	0.08
Week 2	0.11	0.09	0.14
Week 3	0.17	0.14	0.19*
Week 4	0.73	0.35	2.04*
Week 5	4.08	5.13	2.25*
Week 6	2.54	2.50*	0.62*
Week 7	0.50	2.33*	No measure*

Data from three individual monkeys, exenatide plasma levels in nM. *Blood samples containing detectable levels of anti-exenatide antibodies.




Fig. S2 Baseline alcohol and water intake by day

Daily alcohol intake over the baseline periods in the exenatide study (a) and the liraglutide study (c). Daily water intake during the same 4h periods in which alcohol drinking was measured, for the exenatide study (b) and the liraglutide study (d). Total daily water intake was not measured. Data are group means, bar represent s.e.m. Group sizes: exenatide n=11, all others n=12.




Fig. S3 *Monitoring of exenatide plasma levels, main study*

Blood was collected at baseline and after 2 and 4 weeks of treatment, as well as at the end of the experiment. Black arrows indicate blood sampling times. Group sizes: exenatide: n=11, vehicle: n=12.